Intel Corp vs McKesson Corporation — how do they compare? Intel Corp trades at $106.06 (market cap $566.04B), while McKesson Corporation trades at $931.59 (market cap $108.46B). The key difference: Intel Corp is far larger — about 5.2× McKesson Corporation's market cap, and Intel Corp pays the higher dividend (2.24%). Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and McKesson Corporation for 74 Days on average.
| INTC | MCK | |
|---|---|---|
Market Cap | $566.04B | $108.46B |
Volume | 118,475,837 | 712,607 |
Sector | Technology | Health |
52-Week High | $140.94 | $995.69 |
52-Week Low | $33.62 | $725.17 |
Typical Hold Time | 116 Days | 74 Days |
Enterprise Value | $586.85B | $115.00B |
Dividend Yield | 2.24% | 0.4% |
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $113.12, up 0.55% on the day, with a bullish technical signal supported by moving averages. Recent earnings beats and a 222% stock surge in 2026 reflect strong AI momentum and foundry growth, though negative net income and high valuation ratios signal caution. The company's cash flow improved in 2025, but competitive pressures and margin challenges persist.
The outlook hinges on Intel's foundry turnaround gaining traction, with revenue growth and external customer adoption as key catalysts. Risks include intense competition, high debt, and execution uncertainty. Analyst consensus is mixed, with a hold rating dominant, suggesting cautious optimism amid fundamental headwinds.
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →